The expression and possible role of corticotropin-releasing hormone family peptides and their corresponding receptors in gynaecological malignancies and premalignant conditions: a systematic review.

CRH breast cancer cervical cancer endometrial cancer gynaecological cancer stress

Journal

Przeglad menopauzalny = Menopause review
ISSN: 1643-8876
Titre abrégé: Prz Menopauzalny
Pays: Poland
ID NLM: 101263235

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 21 08 2023
accepted: 26 10 2023
medline: 19 1 2024
pubmed: 19 1 2024
entrez: 19 1 2024
Statut: ppublish

Résumé

The aim of this systematic review is to investigate the impact of corticotropin-releasing hormone (CRH) family peptides and their corresponding receptors on human physiology and disease onset, with a specific focus on gynaecological malignancies such as breast, endometrial, ovarian, vulvar, and cervical cancer. A comprehensive systematic review of 3 medical databases was conducted by 2 independent reviewers. We reviewed studies that explored the expression and role of CRH peptides in various aspects of cancer biology, in the context of breast, endometrial, ovarian, vulvar, and cervical cancer. Our findings reveal that CRH family peptides and their receptors, CRHR1 and CRHR2, are expressed in diverse gynaecological tissues, including cancer cells. Notably, we observed differential expression patterns among different gynaecological cancer types and stages, indicating potential associations with tumour aggressiveness and patient prognosis. Furthermore, CRH peptides were found to exert significant influences on critical cellular processes, such as cell proliferation, migration, invasion, and immune response, in gynaecological cancers. These findings highlight the multifaceted roles of CRH family peptides in gynaecological malignancies and emphasize the need for further research in this field. Therefore, understanding the mechanisms underlying the involvement of CRH family peptides in tumourigenesis may open new avenues for targeted therapeutic strategies in gynaecological malignancies.

Identifiants

pubmed: 38239406
doi: 10.5114/pm.2023.133878
pii: 52105
pmc: PMC10793609
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

227-235

Informations de copyright

Copyright © 2023 Termedia.

Déclaration de conflit d'intérêts

The authors report no conflict of interest.

Auteurs

Angelos Dimas (A)

2 Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Chrysoula Margioula-Siarkou (C)

2 Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Anastasia Politi (A)

1 Dermatology Department, "Andreas Syggros" Hospital for Skin Diseases, National and Kapodistrian University of Athens, Athens, Greece.

Alexandros Sotiriadis (A)

2 Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Alexios Papanikolaou (A)

2 Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Konstantinos Dinas (K)

2 Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Stamatios Petousis (S)

2 Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Classifications MeSH